Based on his disruptive technology, Ciloa helps to develop therapeutic monoclonal antibodies and vaccines. Ciloa sorts monomers, homo- or hetero-oligomers of fully native membrane proteins (GPCRs, Ion channels, Kinase receptors, viral Env proteins…) on recombinant exosomes. This tool unlocks several steps of mAb development against membrane proteins, like: i) obtaining fully native antigen, ii) immunization against poor immunogens, iii) robust ELISA screenings, iv) easy SPR characterization